Proteomic analysis in type 2 diabetes patients before and after a very low calorie diet reveals potential disease state and intervention specific biomarkers

PLoS ONE

Volumn 9, Issue 11, 2014, Pages

  Sleddering, Maria A ^a   Markvoort, Albert J ^b   Dharuri, Harish K ^a   Jeyakar, Skhandhan ^b   Snel, Marieke ^a   Juhasz, Peter ^c   Lynch, Moira ^c   Hines, Wade ^c   Li, Xiaohong ^c   Jazet, Ingrid M ^a   Adourian, Aram ^c   Hilbers, Peter A J ^b   Smit, Johannes W A ^a   Van Dijk, Ko Willems ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b EINDHOVEN UNIVERSITY OF TECHNOLOGY   (Netherlands)

^c BG Medicine Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFAMIN PRECURSOR; ALPHA 1 ACID GLYCOPROTEIN 1; ALPHA 1 ANTITRYPSIN; APOLIPOPROTEIN A1; APOLIPOPROTEIN A4; APOLIPOPROTEIN B100; APOLIPOPROTEIN C3; APOLIPOPROTEIN E; BETA2 GLYCOPROTEIN 1; BIOTINIDASE; CHOLESTEROL; COMPLEMENT COMPONENT C3; FIBRINOGEN ALPHA CHAIN; FIBRINOGEN BETA CHAIN; FIBRINOGEN GAMMA CHAIN; HEMOGLOBIN A1C; INSULIN; INTER ALPHA TRYPSIN INHIBITOR HEAVY CHAIN H4; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; LEUCINE RICH ALPHA 2 GLYCOPROTEIN; LYSOZYME; MASP 1 PROTEIN; PIGMENT EPITHELIUM DERIVED FACTOR; PREALBUMIN; PROTEIN; SELENOPROTEIN; SEX HORMONE BINDING GLOBULIN; SOMATOMEDIN BINDING PROTEIN 2; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; BIOLOGICAL MARKER; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C PROTEIN, HUMAN;

ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; EXERCISE; FAT MASS; FEMALE; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN TREATMENT; ISOBARIC TAGS FOR RELATIVE AND ABSOLUTE QUANTITATION; LOW CALORY DIET; MALE; MASS SPECTROMETRY; MULTIPLE REACTION MONITORING; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEOTIDE SEQUENCE; PROTEIN EXPRESSION; PROTEOMICS; TRIACYLGLYCEROL BLOOD LEVEL; VERY LOW CALORY DIET; WAIST CIRCUMFERENCE; WEIGHT REDUCTION; CALORIC RESTRICTION; METABOLISM; MIDDLE AGED;

BIOLOGICAL MARKERS; CALORIC RESTRICTION; DIABETES MELLITUS, TYPE 2; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; MALE; MASS SPECTROMETRY; MIDDLE AGED; PROTEOMICS;

EID: 84912088197     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0112835     Document Type: Article

References (71)

1. Danaei G, Finucane MM, Lu Y, Singh GM, Cowan MJ, et al. (2011) National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants. The Lancet 378: 31-40.
2. Finucane MM, Stevens GA, Cowan MJ, Danaei G, Lin JK, et al. (2012) National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. The Lancet 377: 557-567.
3. Donath MY, Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol 11: 98-107.
4. Matthaei S, Stumvoll M, Kellerer M, Haring HU (2000) Pathophysiology and pharmacological treatment of insulin resistance. Endocr Rev 21: 585-618.
5. Dandona P, Aljada A (2002) A rational approach to pathogenesis and treatment of type 2 diabetes mellitus, insulin resistance, inflammation, and atherosclerosis. The American Journal of Cardiology 90: 27-33.
6. Mokdad AH, Bowman BA, Ford ES, Vinicor F, Marks JS, et al. (2001) The continuing epidemics of obesity and diabetes in the United States. JAMA 286: 1195-1200.
7. CDC (2004) Prevalence of overweight and obesity among adults with diagnosed diabetes-United States, 1988-1994 and 1999-2002. MMWR Morb Mortal Wkly Rep 53: 1066-1068.
8. Karelis AD (2011) Metabolically healthy but obese individuals. The Lancet 372: 1281-1283.
9. Kramer CK, Zinman B, Retnakaran R (2013) Are Metabolically Healthy Overweight and Obesity Benign Conditions?A Systematic Review and Meta-analysis. Annals of Internal Medicine 159: 758-769.
10. Jazet IM, de Craen AJ, van Schie EM, Meinders AE (2007) Sustained beneficial metabolic effects 18 months after a 30-day very low calorie diet in severely obese, insulin-treated patients with type 2 diabetes. Diabetes Research and Clinical Practice 77: 70-76.
11. Snel M, Sleddering MA, Vd Peijl ID, Romijn JA, Pijl H, et al. (2012) Quality of life in type 2 diabetes mellitus after a very low calorie diet and exercise. Eur J Intern Med 23: 143-149.
12. Snel M, Jonker JT, Hammer S, Kerpershoek G, Lamb HJ, et al. (2012) Long-term beneficial effect of a 16-week very low calorie diet on pericardial fat in obese type 2 diabetes mellitus patients. Obesity (Silver Spring) 20: 1572-1576.
13. Snel M, Gastaldelli A, Ouwens DM, Hesselink MK, Schaart G, et al. (2012) Effects of Adding Exercise to a 16-Week Very Low-Calorie Diet in Obese, Insulin-Dependent Type 2 Diabetes Mellitus Patients. J Clin Endocrinol Metab 97: 2512-2520.
14. Herder C, Karakas M, Koenig W (2011) Biomarkers for the Prediction of Type 2 Diabetes and Cardiovascular Disease. Clin Pharmacol Ther 90: 52-66.
15. Lyons TJ, Basu A (2012) Biomarkers in diabetes: hemoglobin A1c, vascular and tissue markers. Transl Res 159: 303-312.
16. Garcia-Ramirez M, Canals F, Hernandez C, Colome N, Ferrer C, et al. (2007) Proteomic analysis of human vitreous fluid by fluorescence-based difference gel electrophoresis (DIGE): a new strategy for identifying potential candidates in the pathogenesis of proliferative diabetic retinopathy. Diabetologia 50: 1294-1303.
17. Kim HJ, Cho EH, Yoo JH, Kim PK, Shin JS, et al. (2007) Proteome analysis of serum from type 2 diabetics with nephropathy. J Proteome Res 6: 735-743.
18. Kriegel TM, Heidenreich F, Kettner K, Pursche T, Hoflack B, et al. (2009) Identification of diabetesand obesity-associated proteomic changes in human spermatozoa by difference gel electrophoresis. Reprod Biomed Online 19: 660-670.
19. Maris M, Overbergh L, Mathieu C (2008) Type 2 diabetes: Gaining insight into the disease process using proteomics. Proteomics Clin Appl 2: 312-326.
20. Rao PV, Reddy AP, Lu X, Dasari S, Krishnaprasad A, et al. (2009) Proteomic identification of salivary biomarkers of type-2 diabetes. J Proteome Res 8: 239-245.
21. Riaz S, Alam SS, Akhtar MW (2010) Proteomic identification of human serum biomarkers in diabetes mellitus type 2. J Pharm Biomed Anal 51: 1103-1107.
22. Riaz S, Alam SS, Srai SK, Skinner V, Riaz A, et al. (2010) Proteomic identification of human urinary biomarkers in diabetes mellitus type 2. Diabetes Technol Ther 12: 979-988.
23. Hammer S, Snel M, Lamb HJ, Jazet IM, van der Meer RW, et al. (2008) Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases myocardial triglyceride content and improves myocardial function. J Am Coll Cardiol 52: 1006-1012.
24. Snel M, van Diepen JA, Stijnen T, Pijl H, Romijn JA, et al. (2011) Immediate and long-term effects of addition of exercise to a 16-week very low calorie diet on low-grade inflammation in obese, insulindependent type 2 diabetic patients. Food Chem Toxicol 49: 3104-3111.
25. Wang Y, Snel M, Jonker JT, Hammer S, Lamb HJ, et al. (2011) Prolonged caloric restriction in obese patients with type 2 diabetes mellitus decreases plasma CETP and increases apolipoprotein AI levels without improving the cholesterol efflux properties of HDL. Diabetes Care 34: 2576-2580.
26. Choe L, D'Ascenzo M, Relkin NR, Pappin D, Ross P, et al. (2007) 8-plex quantitation of changes in cerebrospinal fluid protein expression in subjects undergoing intravenous immunoglobulin treatment for Alzheimer's disease. Proteomics 7: 3651-3660.
27. Juhasz P, Lynch M, Sethuraman M, Campbell J, Hines W, et al. (2011) Semi-targeted plasma proteomics discovery workflow utilizing two-stage protein depletion and off-line LC-MALDI MS/MS. J Proteome Res 10: 34-45.
28. Vandesompele J, De PK, Pattyn F, Poppe B, Van RN, et al. (2002) Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 3: RESEARCH0034.
29. R Development Core Team (2008) R: A language and environment for statistical computing.
30. Bates D, Maechler M, Bolker B (2011) lme4: Linear mixed-effects models using S4 classes. R package version 0.999375-42.
31. Hothorn T, Bretz F, Westfall P (2008) Simultaneous Inference in General Parametric Models. Biom J 50: 346-363.
32. Tso P, Liu M (2004) Apolipoprotein A-IV, food intake, and obesity. Physiol Behav 83: 631-643.
33. Green PH, Glickman RM, Riley JW, Quinet E (1980) Human apolipoprotein A-IV. Intestinal origin and distribution in plasma. J Clin Invest 65: 911-919.
34. Kronenberg F, Stühlinger M, Trenkwalder E, Geethanjali FS, Pachinger O, et al. (2000) Low apolipoprotein A-IV plasma concentrations in men with coronary artery disease. J Am Coll Cardiol 36: 751-757.
35. Quilliot D, Walters E, Guerci B, Fruchart JC, Duriez P, et al. (2001) Effect of the inflammation, chronic hyperglycemia, or malabsorption on the apolipoprotein A-IV concentration in type 1 diabetes mellitus and in diabetes secondary to chronic pancreatitis. Metabolism 50: 1019-1024.
36. Fujimoto K, Cardelli JA, Tso P (1992) Increased apolipoprotein A-IV in rat mesenteric lymph after lipid meal acts as a physiological signal for satiation. Am J Physiol Gas Liv Physiol 262: G1002-G1006.
37. Sun Z, Larson IA, Ordovas JM, Barnard JR, Schaefer EJ (2000) Effects of age, gender, and lifestyle factors on plasma apolipoprotein A-IV concentrations. Atherosclerosis 151: 381-388.
38. Verges BL, Vaillant G, Goux A, Lagrost L, Brun JM, et al. (1994) Apolipoprotein A-IV levels and phenotype distribution in NIDDM. Diabetes Care 17: 810-817.
39. Shen L, Tso P, Woods SC, Sakai RR, Davidson WS, et al. (2007) Hypothalamic apolipoprotein A-IV is regulated by leptin. Endocrinology 148: 2681-2689.
40. Verges B, Guerci B, Durlach V, Galland-Jos C, Paul JL, et al. (2001) Increased plasma apoA-IV level is a marker of abnormal postprandial lipemia: a study in normoponderal and obese subjects. J Lipid Res 42: 2021-2029.
41. Ehnholm C, de Knijff P, Havekes L, Rosseneu M, Menzel HJ, et al. (1994) Genetic polymorphism of apolipoprotein A-IV in five different regions of Europe. Relations to plasma lipoproteins and to history of myocardial infarction: the EARS study. Atherosclerosis 107: 229-238.
42. Culnan DM, Cooney RN, Stanley B, Lynch CJ (2009) Apolipoprotein A-IV, a putative satiety/antiatherogenic factor, rises after gastric bypass. Obesity (Silver Spring) 17: 46-52.
43. Weinberg RB, Dantzker C, Patton CS (1990) Sensitivity of serum apolipoprotein A-IV levels to changes in dietary fat content. Gastroenterology 98: 17-24.
44. Bertile F, Schaeffer C, Le MY, Raclot T, Van DA (2009) A proteomic approach to identify differentially expressed plasma proteins between the fed and prolonged fasted states. Proteomics 9: 148-158.
45. Onat A, Can G, Rezvani R, Cianflone K (2011) Complement C3 and cleavage products in cardiometabolic risk. Clin Chim Acta 412: 1171-1179.
46. Hernandez-Mijares A, Jarabo-Bueno MM, Lopez-Ruiz A, Sola-Izquierdo E, Morillas-Arino C, et al. (2007) Levels of C3 in patients with severe, morbid and extreme obesity: its relationship to insulin resistance and different cardiovascular risk factors. Int J Obes (Lond) 31: 927-932.
47. Yang Y, Lu HL, Zhang J, Yu HY, Wang HW, et al. (2006) Relationships among acylation stimulating protein, adiponectin and complement C3 in lean vs obese type 2 diabetes. Int J Obes (Lond) 30: 439-446.
48. Engstrom G, Hedblad B, Eriksson KF, Janzon L, Lindgarde F (2005) Complement C3 is a risk factor for the development of diabetes: a population-based cohort study. Diabetes 54: 570-575.
49. Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, et al. (2012) A novel mechanism for hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 55: 1103-1113.
50. Barazzoni R, Kiwanuka E, Zanetti M, Cristini M, Vettore M, et al. (2003) Insulin acutely increases fibrinogen production in individuals with type 2 diabetes but not in individuals without diabetes. Diabetes 52: 1851-1856.
51. Ceriello A, Mercuri F, Fabbro D, Giacomello R, Stel G, et al. (1998) Effect of intensive glycaemic control on fibrinogen plasma concentrations in patients with Type II diabetes mellitus. Relation with betafibrinogen genotype. Diabetologia 41: 1270-1273.
52. Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR (1990) Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 120: 672-676.
53. Zhao Y, Zhang J, Zhang J, Wu J (2011) Diabetes mellitus is associated with shortened activated partial thromboplastin time and increased fibrinogen values. PLoS One 6: e16470.
54. Becker A, van der Does FE, van Hinsbergh VW, Heine RJ, Bouter LM, et al. (2003) Improvement of glycaemic control in type 2 diabetes: favourable changes in blood pressure, total cholesterol and triglycerides, but not in HDL cholesterol, fibrinogen, Von Willebrand factor and (pro)insulin. Neth J Med 61: 129-136.
55. Jae SY, Heffernan KS, Lee MK, Fernhall B, Park WH (2008) Relation of cardiorespiratory fitness to inflammatory markers, fibrinolytic factors, and lipoprotein(a) in patients with type 2 diabetes mellitus. Am J Cardiol 102: 700-703.
56. Missov RM, Stolk RP, van der Bom JG, Hofman A, Bots ML, et al. (1996) Plasma fibrinogen in NIDDM: the Rotterdam study. Diabetes Care 19: 157-159.
57. Ernst E (1993) Does weight loss reduce plasma fibrinogen? Br Heart J 70: 116-118.
58. Jacobsson B, Collins VP, Grimelius L, Pettersson T, Sandstedt B, et al. (1989) Transthyretin immunoreactivity in human and porcine liver, choroid plexus, and pancreatic islets. Journal of Histochemistry & Cytochemistry 37: 31-37.
59. Kelleher PC, Phinney SD, Sims EA, Bogardus C, Horton ES, et al. (1983) Effects of carbohydratecontaining and carbohydrate-restricted hypocaloric and eucaloric diets on serum concentrations of retinol-binding protein, thyroxine-binding prealbumin and transferrin. Metabolism 32: 95-101.
60. Ritz P, Becouarn G, Douay O, Salle A, Topart P, et al. (2009) Gastric bypass is not associated with protein malnutrition in morbidly obese patients. Obes Surg 19: 840-844.
61. Ramalho R, Guimaraes C, Gil C, Neves C, Guimaraes JT, et al. (2009) Morbid obesity and inflammation: a prospective study after adjustable gastric banding surgery. Obes Surg 19: 915-920.
62. Scalfi L, Contaldo F, Borrelli R, De CM, Spagnuolo G, et al. (1987) Protein balance during very-lowcalorie diets for the treatment of severe obesity. Ann Nutr Metab 31: 154-159.
63. Pasquali R, Casimirri F, Melchionda N (1987) Protein metabolism in obese patients during very lowcalorie mixed diets containing different amounts of proteins and carbohydrates. Metabolism 36: 1141-1148.
64. Hoffer LJ, Bistrian BR, Young VR, Blackburn GL, Wannemacher RW (1984) Metabolic effects of carbohydrate in low-calorie diets. Metabolism 33: 820-825.
65. Afolabi PR, Jahoor F, Jackson AA, Stubbs J, Johnstone AM, et al. (2007) The effect of total starvation and very low energy diet in lean men on kinetics of whole body protein and five hepatic secretory proteins. Am J Physiol Endocrinol Metab 293: E1580-E1589.
66. Takahashi M, Iwaki D, Kanno K, Ishida Y, Xiong J, et al. (2008) Mannose-Binding Lectin (MBL)-Associated Serine Protease (MASP)-1 Contributes to Activation of the Lectin Complement Pathway. The Journal of Immunology 180: 6132-6138.
67. Tymchuk CN, Tessler SB, Barnard RJ (2000) Changes in sex hormone-binding globulin, insulin, and serum lipids in postmenopausal women on a low-fat, high-fiber diet combined with exercise. Nutr Cancer 38: 158-162.
68. Tymchuk CN, Tessler SB, Aronson WJ, Barnard RJ (1998) Effects of diet and exercise on insulin, sex hormone-binding globulin, and prostate-specific antigen. Nutr Cancer 31: 127-131.
69. Caballero MJ, Mahedero G, Hernandez R, Alvarez JL, Rodriguez J, et al. (1996) Effects of physical exercise on some parameters of bone metabolism in postmenopausal women. Endocr Res 22: 131-138.
70. Caballero MJ, Mena P, Maynar M (1992) Changes in sex hormone binding globulin, high density lipoprotein cholesterol and plasma lipids in male cyclists during training and competition. Eur J Appl Physiol Occup Physiol 64: 9-13.
71. Ding EL, Song Y, Manson JE, Hunter DJ, Lee CC, et al. (2009) Sex hormone-binding globulin and risk of type 2 diabetes in women and men. N Engl J Med 361: 1152-1163.